文献速递心律失常血脂与心血管预防

房颤筛查:证据的呼唤

Screening for atrial fibrillation: a call for evidence.
PubMed 文献 · Eur Heart J · 2020-01-01

房颤是最常见的心律失常,患病率预计未来30年翻倍。房颤使卒中风险增加五倍,抗凝可降低约65%风险,但许多患者未被发现。国际工作组因费用和获益不确定性暂不建议筛查,多项大型随机对照试验正在进行。

要点

  • 房颤患病率预计未来30年翻倍,与人口老龄化和高血压糖尿病等危险因素增加有关。
  • 房颤患者卒中风险增加五倍,符合条件的患者抗凝可降低约65%的卒中风险。
  • 国际工作组目前不建议筛查,主要顾虑费用和系统筛查与常规护理相比获益不确定。

核心结论

  • 房颤筛查能否通过早期抗凝降低缺血性卒中发生率尚缺乏确定性证据,多项大型随机对照试验正在进行。

研究设计与样本

  • 本文为综述,概述当前房颤筛查证据的空白,并总结支持与反对筛查的论据。

主要发现

  • 房颤患病率预计未来30年翻倍,归因于人口结构变化及高血压、糖尿病等危险因素患病率上升。
  • 房颤与卒中风险增加五倍相关,符合条件的患者抗凝治疗可降低约65%的卒中风险。
  • 许多房颤患者因无症状或阵发性房颤而未被发现和未接受治疗。
  • 国际工作组目前不建议筛查,理由包括费用影响以及系统筛查与常规护理相比获益的不确定性。
  • AppleWatch研究显示技术进展使公众可及的自筛查设备日益可负担和易获得。

临床怎么用

  • healthcare professionals应关注新兴数据对诊断路径和治疗的影响。

局限性

  • 目前缺乏系统筛查与常规护理相比的获益和成本效果的确定性证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atrial fibrillation (AF) is the most common cardiac arrhythmia and prevalence is predicted to double over the next 30 years due to changing demographics and the rise in prevalence of risk factors such as hypertension and diabetes. Atrial fibrillation is associated with a five-fold increased stroke risk, but anticoagulation in eligible patients can reduce this risk by around 65%. Many people with AF currently go undetected and therefore untreated, either because they are asymptomatic or because they have paroxysmal AF. Screening has been suggested as one approach to increase AF detection rates and reduce the incidence of ischaemic stroke by earlier initiation of anticoagulation therapy. However, international taskforces currently recommend against screening, citing the cost implications and uncertainty over the benefits of a systematic screening programme compared to usual care. A number of large randomized controlled trials have commenced to determine the cost-effectiveness and clinical benefit of screening using a range of devices and across different populations. The recent AppleWatch study demonstrates how advances in technology are providing the public with self-screening devices that are increasingly affordable and accessible. Health care professionals should be aware of the implications of these emerging data for diagnostic pathways and treatment. This review provides an overview of the gaps in the current evidence and a summary of the arguments for and against screening.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Jones NR, Taylor CJ, Hobbs FDR, et al. Screening for atrial fibrillation: a call for evidence. Eur Heart J. 2020. PMID: 31811716. doi:10.1093/eurheartj/ehz834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。